Regeneron's Lynozyfic Shows 100% Complete Response in AL Amyloidosis Trial
REGN sits 35% above its 52-week low of $476.487.
Summary
Regeneron's Lynozyfic monotherapy achieved a 100% hematologic complete response rate in patients with second-line-plus systemic AL amyloidosis during a Phase 1/2 trial. This rare and fatal disease currently lacks approved therapies after initial treatment failure. The trial also showed significant improvement in renal and cardiac organ function for a majority of patients. These exceptionally strong results de-risk the drug for this new indication, representing a material pipeline win for Regeneron. This follows a consistent stream of positive drug development news for the company. Detailed results will be presented at ASCO on May 29.
At the time of this announcement, REGN was trading at $642.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.4B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.